Join AMRIat Chemspec Europe this year in the SOCMA Pavilion (Booth #G01H), from June 24-25, 2015, in Cologne, Germany, to learn more about our API Manufacturing solutions.
Join Albany Molecular Research Inc. (AMRI) at Chemspec Europe this year in the SOCMA Pavilion (Booth #G01H), from June 24-25, 2015, in Cologne, Germany. Chemspec is the perfect opportunity to learn more about how we can provide you with the essential expertise to support the development and the cGMP manufacture of your custom and complex Active Pharmaceutical Ingredients (API).
To help you progress your complex compounds, our API Manufacturing business is at the ready to support the production of your complex, formulated drug product, from grams to hundreds of kilograms. Our global manufacturing footprint, which also includes manufacturing in India, provides you with access to global markets and low-cost manufacturing of APIs and intermediates.
Core Competencies Include:
High Potency & Pilot Plant Production
We provide full-service GMP-warehousing with ambient, USP, refrigerated and freezer storage conditions, and approach quality on a GMP continuum, ensuring the correct quality measures are in place for each stage of a drug development project. Our capabilities include hydrogenations, esterifications, Friedel-Crafts acylations, low-temperature Grignards, chlorination, bromination, Palladium-catalyzed couplings, chiral resolutions, peptide couplings and others.
Contact Details:
Albany Molecular Research Inc.
Email: Lisa.Peterson@amriglobal.comWeb Address: Click here to schedule a meeting with us at Chemspec Europe in Cologne, Germany
Clinical Supply Planning in Europe - Balancing Cost, Flexibility and Time
December 19th 2024The packaging and distribution of clinical supplies is a fundamental piece to the overall success of a clinical trial, and advance preparation can help establish a more efficient supply chain. Selecting the best geographical location for those activities, however, depends on the clinical trial protocol, business decisions, and even the investigational medicinal product (IMP) being studied.